12,796 Shares in Boston Scientific Corporation $BSX Acquired by Continuum Advisory LLC

Continuum Advisory LLC bought a new position in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 12,796 shares of the medical equipment provider’s stock, valued at approximately $546,000.

A number of other large investors also recently made changes to their positions in the business. Nykredit A S acquired a new stake in Boston Scientific in the 2nd quarter worth about $24,858,000. B. Metzler seel. Sohn & Co. AG lifted its holdings in shares of Boston Scientific by 25.8% during the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 333,583 shares of the medical equipment provider’s stock worth $14,237,000 after acquiring an additional 68,450 shares during the period. Natural Investments LLC boosted its position in shares of Boston Scientific by 1.3% in the second quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock worth $685,000 after acquiring an additional 206 shares during the last quarter. Legacy Financial Advisors Inc. grew its holdings in Boston Scientific by 91.0% in the second quarter. Legacy Financial Advisors Inc. now owns 11,942 shares of the medical equipment provider’s stock valued at $510,000 after purchasing an additional 5,691 shares during the period. Finally, Proficio Capital Partners LLC acquired a new position in Boston Scientific during the second quarter worth approximately $434,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 1.9%

Shares of BSX opened at $47.85 on Friday. The stock’s 50-day moving average is $46.90 and its two-hundred day moving average is $55.74. The stock has a market cap of $69.35 billion, a PE ratio of 19.37, a P/E/G ratio of 1.09 and a beta of 0.57. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has initiated a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BSX. Argus reissued a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Truist Financial cut their target price on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Leerink Partners set a $60.00 price target on Boston Scientific in a research report on Thursday, July 30th. Zacks Research lowered Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Finally, Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $71.62.

Insider Activity at Boston Scientific

In other news, Director Edward Ludwig purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David Habiger purchased 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Shipping operations are being restored after a cyberattack. Boston Scientific has begun resuming product shipments, suggesting the disruption may be contained and reducing concerns about a prolonged impact on revenue and customer relationships. Boston Scientific begins to restore shipping after cyberattack
• Positive Sentiment: Interventional cardiology and vascular therapy growth remains a key support. ICVT sales reportedly increased 15%, helped by demand for coronary therapies, new devices and strategic deals. Sustained momentum in this business could help offset pressure elsewhere. Boston Scientific’s ICVT Business Gains Momentum
• Positive Sentiment: Clinical progress may expand the heart-failure opportunity. The completion of the LUX-Dx TRENDS study provides additional data on Boston Scientific’s implantable monitoring technology, although the commercial impact depends on study results and adoption. Boston Scientific’s LUX-Dx TRENDS Study
• Neutral Sentiment: Heavy call-option activity indicates some traders are positioning for a rebound, but options flows do not guarantee future stock performance. Stock Traders Buy High Volume of Call Options on Boston Scientific
• Negative Sentiment: Product recalls remain a significant overhang. Boston Scientific recalled Infinion CX spinal-cord-stimulator leads because of fracture risk following 1,081 injury reports, while additional worldwide recalls could increase costs, regulatory scrutiny and liability exposure. Boston Scientific Recalls Spinal Cord Stimulator Leads
• Negative Sentiment: The cyberattack disrupted shipments, and concerns about weaker 2026 guidance and broader business pressure have weighed on the outlook. The recent decline before the latest recovery reflects investor caution despite Boston Scientific’s prior earnings and revenue beats. Cyberattack and Weak 2026 Outlook Weigh on BSX

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.